CVKD News & Events

Cadrenal Therapeutics highlighted recent scientific findings demonstrating the potential of its first-in-class 12-lipoxygenase, 12-LOX, inhibitor, CAD-1005, to target inflammatory consequences of obesity and Type 2 diabetes. The study builds on prior animal research showing that inhibiting 12-LOX with CAD-1005 delays the onset of autoimmune diabetes in non-obese diabetic mice. The findings highlight 12-LOX as a key factor in obesity-associated inflammation and suggest that 12-LOX inhibition could be a therapeutic strategy to improve glucose homeostasis and peripheral inflammation in the setting of obesity and type 2 diabetes.

Cadrenal Therapeutics provided additional perspectives on development opportunities following its recent pipeline expansion with the addition of 12-LOX inhibitors. As previously announced, Cadrenal recently acquired a portfolio of selective 12-LOX inhibitors, including oral candidates. Encouraging recent data from a blinded, placebo-controlled Phase 2 study of CAD-1005, a parenteral 12-LOX inhibitor, in heparin-induced thrombocytopenia demonstrated a reduction in thrombotic events on a background of standard anticoagulants, with an End-of-Phase 2 meeting scheduled for later this month.

Cadrenal Therapeutics announced results from a Phase 2 trial evaluating CAD-1005 in patients with heparin-induced thrombocytopenia, a severe pro-thrombotic reaction to heparin, the most commonly used parenteral anticoagulant. Highlights: Primary Endpoint: Thrombotic events continued to occur even after platelet count recovery in both groups. Platelet recovery rates were similar between the CAD-1005 and placebo arms. Platelet count recovery did not appear to be a surrogate marker for clinical efficacy. Key Secondary Endpoint: A high rate of thrombotic events was observed in the placebo group, with fewer thrombotic events in the CAD-1005 group, although the study was not powered to detect statistical significance. Adding an inhibitor of 12-LOX to standard anticoagulants to block the immunological mechanisms driving HIT may be more effective than anticoagulants alone in preventing thrombotic events.

Cadrenal Therapeutics highlighted the significant unmet medical need in heparin-induced thrombocytopenia and underscored the promise of its recently acquired investigational drug candidate, VLX-1005. Cadrenal Therapeutics acquired VLX-1005 in December 2025, recognizing its potential to transform the treatment landscape for HIT and other immune-mediated thrombotic disorders. Emerging data from a recent Phase 2 clinical trial evaluating VLX-1005 in individuals with suspected HIT suggest that VLX-1005 may reduce thrombotic complications, supporting its further development as a novel, mechanism-based therapy. Early trial results suggest that selective 12-LOX inhibition may offer a differentiated approach by addressing the immune thrombotic drivers of disease rather than solely suppressing coagulation.